AUTHOR=Vaccher Stefanie J. , Gianacas Christopher , Templeton David J. , Poynten Isobel M. , Haire Bridget G. , Ooi Catriona , Foster Rosalind , McNulty Anna , Grulich Andrew E. , Zablotska Iryna B. , On Behalf of the PRELUDE Study Team , Carr Andrew , Grulich Andrew , McNulty Anna , Mackie Brent , Pell Cathy , Ooi Catriona , Ching Cheung (Yvonne) , Gianacas Chris , Templeton David , Murphy Dean , Wright Edwina , Prestage Garrett , Poynten Isobel (Mary) , de Wit John , Kaldor John , McAllister John , Mayer Kenneth , Bloch Mark , Holt Martin , Ryder Nathan , Guy Rebecca , Foster Rosalind , Vaccher Stefanie TITLE=Baseline Preferences for Daily, Event-Driven, or Periodic HIV Pre-Exposure Prophylaxis among Gay and Bisexual Men in the PRELUDE Demonstration Project JOURNAL=Frontiers in Public Health VOLUME=5 YEAR=2017 URL=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2017.00341 DOI=10.3389/fpubh.2017.00341 ISSN=2296-2565 ABSTRACT=Introduction

The effectiveness of daily pre-exposure prophylaxis (PrEP) is well established. However, there has been increasing interest in non-daily dosing schedules among gay and bisexual men (GBM). This paper explores preferences for PrEP dosing schedules among GBM at baseline in the PRELUDE demonstration project.

Materials and methods

Individuals at high-risk of HIV were enrolled in a free PrEP demonstration project in New South Wales, Australia, between November 2014 and April 2016. At baseline, they completed an online survey containing detailed behavioural, demographic, and attitudinal questions, including their ideal way to take PrEP: daily (one pill taken every day), event-driven (pills taken only around specific risk events), or periodic (daily dosing during periods of increased risk).

Results

Overall, 315 GBM (98% of study sample) provided a preferred PrEP dosing schedule at baseline. One-third of GBM expressed a preference for non-daily PrEP dosing: 20% for event-driven PrEP, and 14% for periodic PrEP. Individuals with a trade/vocational qualification were more likely to prefer periodic to daily PrEP [adjusted odds ratio (aOR) = 4.58, 95% confidence intervals (95% CI): (1.68, 12.49)], compared to individuals whose highest level of education was high school. Having an HIV-positive main regular partner was associated with strong preference for daily, compared to event-driven PrEP [aOR = 0.20, 95% CI: (0.04, 0.87)]. Participants who rated themselves better at taking medications were more likely to prefer daily over periodic PrEP [aOR = 0.39, 95% CI: (0.20, 0.76)].

Discussion

Individuals’ preferences for PrEP schedules are associated with demographic and behavioural factors that may impact on their ability to access health services and information about PrEP and patterns of HIV risk. At the time of data collection, there were limited data available about the efficacy of non-daily PrEP schedules, and clinicians only recommended daily PrEP to study participants. Further research investigating how behaviours and PrEP preferences change correspondingly over time is needed.

Trial registration

ClinicalTrials.gov NCT02206555. Registered 28 July 2014.